Ras (G12D Mutant) Antibody [C11A12]

Catalog No.: F6955

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:500-1:3000
    1:25-1:100
    Application
    WB, IHC
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    21 kDa 22 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    Ras (G12D Mutant) Antibody [C11A12] detects endogenous levels of total Ras (G12D Mutant) protein.
    Clone
    C11A12
    Synonym(s)
    GTPase Kras, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, KRAS, KRAS2, RASK2
    Background
    Ras G12D represents an oncogenic mutant form of the small GTPase K‑Ras, a member of the RAS family of guanine nucleotide–binding switches that regulate mitogenic and survival signaling downstream of receptor tyrosine kinases and other upstream cues. The mutation replaces glycine with aspartate at position 12 within the P‑loop of the G‑domain, in close proximity to the nucleotide and catalytic machinery, and alters local side‑chain packing, hydrogen‑bonding, and electrostatic environment so that the catalytic site adopts conformations that no longer support efficient GTP hydrolysis in the presence of GTPase‑activating proteins. The mutant protein maintains the canonical RAS fold with a G‑domain that binds GTP or GDP and a flexible switch I and switch II region that mediate effector recognition, yet the G12D substitution increases the occupancy of active‑state conformations and disrupts key contacts required for transition state stabilization, which stabilizes the GTP‑bound signaling‑competent form and reduces responsiveness to GAP‑catalyzed inactivation. The activated G12D mutant engages Raf kinases through the RAS‑binding domain, initiating the Raf–MEK–ERK cascade that drives transcriptional programs for proliferation and survival, and at the same time couples to PI3K through direct interaction, supporting the PI3K–AKT axis that promotes growth and cell survival. Additional effector pathways that respond to RAS G12D include Ral guanine nucleotide exchange factors and other downstream nodes, providing multiple parallel outputs that reinforce each other to maintain a proliferative, anti‑apoptotic state. Structural analyses of K‑Ras G12D complexes show that the aspartate side chain at position 12 introduces steric and electrostatic clashes near the γ‑phosphate of GTP and the arginine finger of GAPs, explaining the impaired catalytic geometry while preserving high affinity for GTP and GDP, so that the protein cycles poorly back to the GDP‑bound inactive state and accumulates in an on state that is competent for effector binding. This mutant signaling behavior sustains chronic activation of MAPK and PI3K pathways, which increases cell cycle entry, resistance to apoptotic cues, and altered differentiation patterns, and positions KRAS G12D as a dominant driver of tumorigenesis in tissues where RAS pathway input controls epithelial homeostasis. Endogenous expression of oncogenic K‑Ras G12D stimulates proliferation of epithelial cells and expands progenitor compartments through combined input from Raf–MEK–ERK and PI3K–AKT cascades, without requiring additional upstream receptor hyperactivation, and this property distinguishes the mutant from wild‑type RAS, which depends on tightly regulated growth factor signals.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください